| abstract |
Compounds of the general formula (I) which are effective as PDE4 inhibitors in the treatment of diseases affected by eosinophil activation and degranulation, in particular in the treatment of asthma, chronic bronchitis and chronic obstructive pulmonary disease (where j is K is 0 or 1; m is 0, 1, 2, 3; n is 1 or 2; W 1 is -O-; -S (= O ) t -; - N (R 3) - are either (provided that t is either 0, 1, 2); W 2 is, -O-CR a R B - is either or not present; Y is, = C (R 1 a) - or - [N → (O) k ] - (k is 0 or 1) be; R A and R B are, -H; -F ; -CF 3 ;-( C 1 -C 4 ) alkyl ;-( C 3 -C 7) cycloalkyl; phenyl; is any one of benzyl, cycloalkyl , Phenyl, benzyl, 0-3 substituents R are substituted with 10; may alternatively R A and R B, together with (but when m is 1 only), forms a spiro moiety; R C and R D, except that one should not not -H be the same meanings as R a and R B; R 1 and R 2, -H; -F; -Cl; -CN ; -NO 2 ;-( C 1 -C 4) alkyl ;-( C 2 -C 4) alkynyl; fluorinated - (C 1 -C 3) alkyl; -OR 16; -C (= O ) NR 22 a R 22 b be either; R 3 is, -H ;-( C 1 -C 3) alkyl; be either -OR 16;; phenyl; benzyl R 4, R 5, R 6 are other in addition to meaning, together to be able to form the general formula (II); G 1 is a saturated or unsaturated A ring system, in some cases one of the carbon atoms therein, N, O, may be substituted by heteroatoms selected from among S; G 2 is a saturated or unsaturated carbocyclic ring A system wherein one carbon atom is optionally replaced by a heteroatom selected from N, O, S; E is selected from general formula (III)) . |